Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia.
about
Clinical implications of the molecular genetics of chronic lymphocytic leukemiaThe biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemiaGenomic and epigenomic heterogeneity in chronic lymphocytic leukemiaIntegrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemiaGenomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome.SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage.Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemiaDeep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia.Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression.State-of-the-Art Management of Patients Suffering from Chronic Lymphocytic Leukemia.A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia.T-cell number and subtype influence the disease course of primary chronic lymphocytic leukaemia xenografts in alymphoid mice.Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia.Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive diseaseClonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemiaCross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma.Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.Patients' Preferences for Genomic Diagnostic Testing in Chronic Lymphocytic Leukaemia: A Discrete Choice ExperimentIssues surrounding the health economic evaluation of genomic technologies.Clinical application of targeted and genome-wide technologies: can we predict treatment responses in chronic lymphocytic leukemia?Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients.Lessons from next-generation sequencing analysis in hematological malignancies.Crambled: A Shiny application to enable intuitive resolution of conflicting cellularity estimates.Chronic lymphocytic leukemia: Time to go past genomics?Clinical Trials in the Genomic Era.Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness AnalysisNext-generation sequencing of cancer consensus genes in lymphoma.Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia.How I treat patients with relapsed chronic lymphocytic leukaemia.
P2860
Q26830955-B01573CE-88A9-4343-8F11-370D8A9494E5Q27024411-807265BE-671B-4775-A0E7-AED379E0204BQ28087672-7FB83E58-B5BA-4E5C-9E9A-F9FC29D22E2DQ28394721-F7D45BD3-5FF0-4604-A3A1-6E1DCAA46569Q30833823-6ADCECF5-09F2-4A34-8CC9-275419DE2ED8Q34391609-28328ACE-A3F5-4D3A-8B1B-7EFA5E9DA2D2Q34453174-026F7B42-52BC-4561-B0BF-82ED3A9749F9Q34974058-EBF94F8C-0E14-4306-AC35-63F2C8F0BB52Q34998866-816C4B5A-4095-4C8B-9E6F-9C1D42EF200BQ35860550-DDEA86A3-0171-4223-A56D-8E3EE96EB9C0Q35984259-A2244569-26BB-49E7-B64D-562B8ED1EA26Q36245171-EA443E87-A213-4391-AF45-BAD8697A24C2Q36799831-D2F05920-043A-4FAE-874E-68DC39E0409BQ36884141-2611258B-21D5-45A2-A483-647C7E578295Q36906625-4B8A3A09-1B57-4125-AFDE-F4701673A90EQ37132882-D0B2E223-2EAB-47A1-8A5D-8287B1C94678Q37255665-9FFC9742-B23D-47BB-8444-87FC05DF602EQ37410709-57E1435D-2BDE-4208-A1FA-81DB503EB131Q37541151-EB295C2E-9D68-4860-B4B0-5C1F87F327C2Q37618663-7953BE9B-F64D-41BF-BE58-15BB1A2B8D57Q37649648-2A012484-85DF-4A7A-A616-80F24C967751Q38123015-AD288E33-C345-4C48-A6E2-463C33A2B39EQ38615870-F582AFDF-5504-4F6F-8A06-3199B06231E4Q38708220-74B1259A-AF2C-4B1A-87C6-A65890D1E38FQ38905607-432D811C-B059-499B-9AD9-10622EEF59ECQ38970612-7AF9589E-223A-4896-9953-11491B77F2E2Q41310328-0F28C4F4-0342-4C60-8C66-D24B5376F045Q44970197-DBADA079-746E-40EE-9C5D-297398106174Q46339557-A4CA9102-37BC-4E53-93F3-8E30B2A31327Q54348577-AAADE229-E2F1-4BF7-86CC-187D7D5D947A
P2860
Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Quantification of subclonal di ...... chronic lymphocytic leukemia.
@ast
Quantification of subclonal di ...... chronic lymphocytic leukemia.
@en
type
label
Quantification of subclonal di ...... chronic lymphocytic leukemia.
@ast
Quantification of subclonal di ...... chronic lymphocytic leukemia.
@en
prefLabel
Quantification of subclonal di ...... chronic lymphocytic leukemia.
@ast
Quantification of subclonal di ...... chronic lymphocytic leukemia.
@en
P2093
P2860
P356
P1433
P1476
Quantification of subclonal di ...... chronic lymphocytic leukemia.
@en
P2093
A R Pettitt
C C Holmes
D G Oscier
E Sadighi Akha
P2860
P2888
P304
P356
10.1038/LEU.2012.13
P577
2012-01-19T00:00:00Z
P5875
P6179
1036314214